Best Sarclisa (Isatuximab) Medicine in India

Sarclisa (Isatuximab) is a targeted anticancer treatment used in combination with other treatments for adults with multiple myeloma, a type of blood cancer that affects plasma cells. It is used in specific treatment settings depending on the patient's previous therapy and overall condition. By targeting a protein called CD38 found on multiple myeloma cells, Sarclisa helps reduce the number of abnormal plasma cells and control the progression of the disease.

Sarclisa (Isatuximab) is a monoclonal antibody that specifically binds to CD38 on the surface of multiple myeloma cells. This binding can directly interfere with cancer cell survival and also activate the body's immune system to recognize and destroy abnormal plasma cells. Through these actions, Isatuximab helps reduce the cancerous plasma cell population and supports control of multiple myeloma.

Sarclisa (Isatuximab) is administered by a trained healthcare professional according to the treatment schedule prescribed by your doctor. You may receive other treatments before or alongside Sarclisa to help prevent or reduce infusion-related reactions and other side effects. Regular blood tests and medical examinations may be required to monitor blood cell counts, treatment response, and overall health. Inform your doctor about all medical conditions and medicines, vitamins, herbal products, or supplements you are taking, and report any unusual or worsening symptoms promptly.

Treatment of Multiple Myeloma

Sarclisa (Isatuximab) is used in combination with other anticancer treatments to treat adults with multiple myeloma, a cancer of plasma cells. It targets the CD38 protein present on multiple myeloma cells and helps the immune system identify and destroy these abnormal cells. By reducing the number of cancerous plasma cells, Sarclisa (Isatuximab) helps control disease progression and may help improve treatment response in eligible patients with multiple myeloma.

Some side effects of Sarclisa (Isatuximab) may improve as the body adjusts to the treatment. Consult your doctor if any side effect persists, becomes severe, or causes concern.

Common Side Effects of Sarclisa (Isatuximab)

Sarclisa (Isatuximab) is given as an intravenous infusion by a doctor or trained healthcare professional. It should not be self-administered. Your doctor will determine the appropriate treatment schedule based on your condition and the other treatments you are receiving. Other medicines may be given before Sarclisa to help reduce the risk of infusion-related reactions. You will be monitored during and after the infusion for any signs of a reaction.

Sarclisa (Isatuximab) is a monoclonal antibody that targets the CD38 protein found on multiple myeloma cells. By binding to CD38, it can directly interfere with the survival of abnormal plasma cells and activate immune mechanisms that help the body recognize and destroy these cancer cells. This reduces the number of malignant plasma cells and helps slow the progression of multiple myeloma.

• Keep the unopened vial refrigerated between 2°C and 8°C.
• Do not allow the vial to freeze, and retain it in the original carton to protect it from light.
• After dilution, the infusion solution may be refrigerated at 2°C to 8°C for up to 48 hours or kept at room temperature for up to 8 hours.
• Store the medicine in a secure place that is inaccessible to children.

Alcohol CONSULT YOUR DOCTOR

Consult your doctor before consuming alcohol during treatment with Sarclisa (Isatuximab).

Pregnancy CONSULT YOUR DOCTOR

Sarclisa may cause harm to an unborn baby. Inform your doctor if you are pregnant or planning to become pregnant. Use effective contraception during treatment and for the recommended period after the last dose, as advised by your doctor.

Breastfeeding CONSULT YOUR DOCTOR

Breastfeeding is not recommended during treatment with Sarclisa. Consult your doctor for guidance on when breastfeeding can be safely resumed.

Driving CONSULT YOUR DOCTOR

Sarclisa may cause fatigue, dizziness, or other effects that can affect your ability to drive safely. Avoid driving if your alertness or ability to concentrate is affected.

Kidney CAUTION

Inform your doctor if you have kidney problems before starting treatment with Sarclisa. Your doctor may recommend additional monitoring based on your kidney function.

Liver CAUTION

Tell your doctor if you have liver problems before starting treatment with Sarclisa. Your doctor may recommend additional monitoring based on your liver function.

• Sarclisa (Isatuximab) is given by a healthcare professional, so attend all scheduled treatment appointments.
• Inform your doctor about all medicines, vitamins, herbal products, and supplements you are taking before starting treatment.
• Follow your doctor's advice and attend regular blood tests to monitor your blood cell counts and treatment response.
• Report fever, chills, cough, breathing difficulties, or other signs of infection promptly.
• Tell your doctor or nurse immediately if you develop flushing, rash, dizziness, swelling, or breathing problems during or after the infusion.
• Read More About - Sarclisa (Isatuximab) from Pharma Five.

Pharma Five, can assist patients in arranging the import of Sarclisa (Isatuximab) in small quantities for personal use. To facilitate the process, the applicant is required to submit an application in Form 12A along with a prescription from a Registered Medical Practitioner (RMP).

Pharma Five provides specialized pharmaceutical consultancy and facilitation services for patients seeking access to Sarclisa (Isatuximab) and other medicines through the required import procedures. Pharma Five provides extensive pharmaceutical service coverage across India, serving patients and healthcare requirements in prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.